Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02381886 | A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | PHASE1 | ACTIVE NOT_RECRUITING | 166 | — | — | Mar 6, 2015 | Oct 31, 2030 | Apr 13, 2026 | 16 | United States, Australia +6 |
To estimate the maximum tolerated dose/recommended dose for expansion (MTD/RDE)
| Arm | Type | Description |
|---|---|---|
| IDH305 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IDH305 | DRUG | - |
Inclusion Criteria: * Documented IDH1R132-mutant tumors * ECOG performance status ≤ 2 Exclusion Criteria: * Patients who have received prior treatment with a mutant-specific IDH1 inhibitor (with the exception of glioma patients) * Medical conditions that would prevent the patient's participation ...